CCNC

Summary

CCNC (cyclin C, HGNC:1581) is a protein-coding gene on chromosome 6q16.2, encoding Cyclin-C (P24863). Component of the Mediator complex, a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes. It is a selective cancer dependency (DepMap: 27.1% of cell lines).

The protein encoded by this gene is a member of the cyclin family of proteins. The encoded protein interacts with cyclin-dependent kinase 8 and induces the phophorylation of the carboxy-terminal domain of the large subunit of RNA polymerase II. The level of mRNAs for this gene peaks in the G1 phase of the cell cycle. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 892 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 41 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 1
• Druggable target: yes — 4 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 27.1% of screened cell lines
• MANE Select transcript: NM_005190

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1581
Approved symbol	CCNC
Name	cyclin C
Location	6q16.2
Locus type	gene with protein product
Status	Approved
Aliases	CycC
Ensembl gene	ENSG00000112237
Ensembl biotype	protein_coding
OMIM	123838
Entrez	892

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 22 protein_coding, 4 retained_intron, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000326298, ENST00000369217, ENST00000369220, ENST00000482541, ENST00000484049, ENST00000486428, ENST00000518714, ENST00000519617, ENST00000520371, ENST00000520429, ENST00000521017, ENST00000523310, ENST00000523541, ENST00000523639, ENST00000523799, ENST00000523961, ENST00000523985, ENST00000524049, ENST00000627680, ENST00000882415, ENST00000882416, ENST00000882417, ENST00000882418, ENST00000882419, ENST00000882420, ENST00000930284, ENST00000930285, ENST00000930286, ENST00000962620, ENST00000962621

RefSeq mRNA: 3 — MANE Select: NM_005190 NM_001013399, NM_001363537, NM_005190

CCDS: CCDS34502, CCDS47461, CCDS87420

Canonical transcript exons

ENST00000520429 — 12 exons

Exon	Start	End
ENSE00002120300	99568496	99568660
ENSE00003514289	99558497	99558548
ENSE00003523925	99549508	99549575
ENSE00003577908	99550218	99550309
ENSE00003585134	99550993	99551028
ENSE00003590914	99546395	99546474
ENSE00003600182	99542387	99543609
ENSE00003656337	99561367	99561436
ENSE00003681803	99551840	99551895
ENSE00003683555	99561597	99561681
ENSE00003689363	99545112	99545230
ENSE00003690529	99562842	99562948

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 98.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 39.7780 / max 354.5567, expressed in 1816 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
74815	19.6777	1805
74814	15.6005	1773
74816	4.0250	1531
204113	0.4748	262

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	98.84	gold quality
oral cavity	UBERON:0000167	98.24	gold quality
corpus epididymis	UBERON:0004359	98.02	gold quality
jejunal mucosa	UBERON:0000399	97.64	gold quality
islet of Langerhans	UBERON:0000006	97.22	gold quality
nasal cavity epithelium	UBERON:0005384	97.21	gold quality
adrenal tissue	UBERON:0018303	97.04	gold quality
mucosa of sigmoid colon	UBERON:0004993	96.93	gold quality
upper leg skin	UBERON:0004262	96.91	gold quality
caput epididymis	UBERON:0004358	96.86	gold quality
nasal cavity mucosa	UBERON:0001826	96.85	gold quality
amniotic fluid	UBERON:0000173	96.73	gold quality
colonic mucosa	UBERON:0000317	96.58	gold quality
pancreas	UBERON:0001264	96.55	gold quality
body of pancreas	UBERON:0001150	96.53	gold quality
type B pancreatic cell	CL:0000169	96.51	gold quality
epithelium of nasopharynx	UBERON:0001951	96.36	gold quality
nephron tubule	UBERON:0001231	96.29	gold quality
mammalian vulva	UBERON:0000997	96.26	gold quality
penis	UBERON:0000989	96.22	gold quality
hair follicle	UBERON:0002073	96.08	gold quality
choroid plexus epithelium	UBERON:0003911	96.08	gold quality
pigmented layer of retina	UBERON:0001782	96.01	gold quality
tongue squamous epithelium	UBERON:0006919	95.95	gold quality
upper arm skin	UBERON:0004263	95.94	gold quality
saliva-secreting gland	UBERON:0001044	95.87	gold quality
seminal vesicle	UBERON:0000998	95.82	gold quality
esophagus squamous epithelium	UBERON:0006920	95.78	gold quality
gall bladder	UBERON:0002110	95.76	gold quality
pharyngeal mucosa	UBERON:0000355	95.75	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-7008	no	426.88
E-CURD-89	no	285.89
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
HES1	Activation

Upstream regulators (CollecTRI, top): CREB1, STOX1, YBX1

miRNA regulators (miRDB)

108 targeting CCNC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-335-3P	99.93	73.36	4958

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 27.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 18)

• The present observations suggest different cellular functions of cyclin C in neurons and astrocytes in alzheimer’s disease. (PMID:12600719)
• A cellular pool of cyclin C combines with cdk3 to stimulate pRb phosphorylation at S807/811 during the G0/G1 transition, and this phosphorylation is required for cells to exit G0 efficiently. (PMID:15084261)
• Identification of multiple 1alpha,25(OH)2D3 response elements in the cyclin C promoter. (PMID:15863722)
• Physical chromosome mapping of the deleted region of chromosome 6 suggests that CCNC is a candidate tumor suppressor gene. (PMID:17089020)
• C2 isoform may play a presently unexplored and important role in mammalian testis and probably this isoform is the one that is mainly implicated in cell cycle regulation. (PMID:17385550)
• Data suggests that the primary regulation of Cyclin C by all-trans RA and Forskolin mediates some of the cell cycle control actions of these compounds. (PMID:19683536)
• Studies establish cyclin C as a critical regulator of the G(0)/G(1) transition of human HSPCs and suggest that modulating cyclin C levels may be useful for HSC expansion and more efficient engraftment. (PMID:19967789)
• 2.2-A crystal structure of CDK8/CycC in complex with sorafenib; CDK8 structure reveals a unique CycC recognition helix that explains the specificity of the CDK8/CycC pair and discrimination among the highly promiscuous binding in the CDK/cyclin family (PMID:21806996)
• Silencing beta-catenin gene may induce changes of cell cycle and in cyclin B1 and cyclin C protein expression. (PMID:22024040)
• analysis of the structure-kinetic relationship of the cyclin-dependent kinase 8 (CDK8)/cyclin C (CycC) complex (PMID:23630251)
• Cancer-mediated CDK8 point mutations (D173A and D189N) change the binding pattern of cdk8 to its partner, CycC. (PMID:24754906)
• cyclin-C-CDK complexes phosphorylate the Notch1 intracellular domain (ICN1) and promote ICN1 degradation (PMID:25344755)
• results suggest that CCNC temporarily protects SRC-2 against degradation and this event is involved in the transcriptional regulation of SRC-2 cell cycle target genes. (PMID:25986860)
• our results suggest that mTORC1 activation in NAFLD and insulin resistance results in down-regulation of the CDK8-CycC complex and elevation of lipogenic protein expression. (PMID:26042770)
• Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19. (PMID:29440396)
• cyclin C binding stimulates the reduction of low-GTPase activity Drp1 oligomers into dimers capable of producing high-GTPase activity filaments. (PMID:30516433)
• Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2. (PMID:34197614)
• Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress. (PMID:34329458)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccnc	ENSDARG00000009607
mus_musculus	Ccnc	ENSMUSG00000028252
rattus_norvegicus	Ccnc	ENSRNOG00000007719

Protein

Protein identifiers

Cyclin-C — P24863 (reviewed: P24863)

Alternative names: SRB11 homolog

All UniProt accessions (11): P24863, E5RFK5, E5RFX8, E5RHL8, E5RI39, E5RIH8, G5E954, H0YBQ5, J3KP90, Q5JV82, Q7Z4L3

UniProt curated annotations — full annotation on UniProt →

Function. Component of the Mediator complex, a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Binds to and activates cyclin-dependent kinase CDK8 that phosphorylates the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAp II), which may inhibit the formation of a transcription initiation complex.

Subunit / interactions. Component of the Mediator complex, which is composed of MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct module termed the CDK8 module. Mediator containing the CDK8 module is less active than Mediator lacking this module in supporting transcriptional activation. Individual preparations of the Mediator complex lacking one or more distinct subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and TRAP. The cylin/CDK pair formed by CCNC/CDK8 also associates with the large subunit of RNA polymerase II.

Subcellular location. Nucleus.

Tissue specificity. Highest levels in pancreas. High levels in heart, liver, skeletal muscle and kidney. Low levels in brain.

Similarity. Belongs to the cyclin family. Cyclin C subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P24863-1	1	yes
P24863-2	2

RefSeq proteins (3): NP_001013417, NP_001350466, NP_005181* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006671	Cyclin_N	Domain
IPR013763	Cyclin-like_dom	Domain
IPR031658	Cyclin_C_2	Domain
IPR036915	Cyclin-like_sf	Homologous_superfamily
IPR043198	Cyclin/Ssn8	Family

Pfam: PF00134, PF16899

UniProt features (28 total): helix 15, turn 6, chain 1, domain 1, strand 1, region of interest 1, compositionally biased region 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

36 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
5XS2	X-RAY DIFFRACTION	2.04
4F6U	X-RAY DIFFRACTION	2.1
9H8S	X-RAY DIFFRACTION	2.16
5ICP	X-RAY DIFFRACTION	2.18
6R3S	X-RAY DIFFRACTION	2.19
6Y0A	X-RAY DIFFRACTION	2.19
3RGF	X-RAY DIFFRACTION	2.2
4F7S	X-RAY DIFFRACTION	2.2
5CEI	X-RAY DIFFRACTION	2.24
5IDN	X-RAY DIFFRACTION	2.26
5XQX	X-RAY DIFFRACTION	2.3
5HNB	X-RAY DIFFRACTION	2.35
5FGK	X-RAY DIFFRACTION	2.36
5HBE	X-RAY DIFFRACTION	2.38
4F6W	X-RAY DIFFRACTION	2.39
5HVY	X-RAY DIFFRACTION	2.39
4CRL	X-RAY DIFFRACTION	2.4
6T41	X-RAY DIFFRACTION	2.45
6QTJ	X-RAY DIFFRACTION	2.48
5HBH	X-RAY DIFFRACTION	2.5
9H8C	X-RAY DIFFRACTION	2.57
4F6S	X-RAY DIFFRACTION	2.6
4F7J	X-RAY DIFFRACTION	2.6
5I5Z	X-RAY DIFFRACTION	2.6
5BNJ	X-RAY DIFFRACTION	2.64
4F7N	X-RAY DIFFRACTION	2.65
5IDP	X-RAY DIFFRACTION	2.65
4G6L	X-RAY DIFFRACTION	2.7
6QTG	X-RAY DIFFRACTION	2.7
6TPA	X-RAY DIFFRACTION	2.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P24863-F1	92.05	0.88

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 275

Function

Pathways and Gene Ontology

Reactome pathways

34 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-212436	Generic Transcription Pathway
R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation
R-HSA-9833110	RSV-host interactions
R-HSA-9841922	MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
R-HSA-1266738	Developmental Biology
R-HSA-1430728	Metabolism
R-HSA-157118	Signaling by NOTCH
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-170834	Signaling by TGF-beta Receptor Complex
R-HSA-1980143	Signaling by NOTCH1
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2644603	Signaling by NOTCH1 in Cancer
R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-556833	Metabolism of lipids
R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers
R-HSA-5663205	Infectious disease
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-9006936	Signaling by TGFB family members
R-HSA-9818564	Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
R-HSA-9820952	Respiratory Syncytial Virus Infection Pathway

MSigDB gene sets: 234 (showing top): REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, KALMA_E2F1_TARGETS, REACTOME_SIGNALING_BY_NOTCH, HORIUCHI_WTAP_TARGETS_DN, REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX, ENK_UV_RESPONSE_KERATINOCYTE_UP, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE, KYNG_DNA_DAMAGE_DN, BROWNE_HCMV_INFECTION_16HR_UP, GOBP_NEGATIVE_REGULATION_OF_NOTCH_SIGNALING_PATHWAY, PUJANA_CHEK2_PCC_NETWORK, CATTTCA_MIR203, MILI_PSEUDOPODIA_HAPTOTAXIS_UP

GO Biological Process (4): G0 to G1 transition (GO:0045023), negative regulation of Notch signaling pathway (GO:0045746), positive regulation of transcription by RNA polymerase II (GO:0045944), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (3): cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (5): cyclin-dependent protein kinase holoenzyme complex (GO:0000307), nucleus (GO:0005634), nucleoplasm (GO:0005654), mediator complex (GO:0016592), CKM complex (GO:1990508)

Reactome top-level categories

Rollup of top-17 pathways:

Category	Pathways
Regulation of lipid metabolism by PPARalpha	1
Signaling by NOTCH1	1
RNA Polymerase II Transcription	1
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	1
Signaling by NOTCH1 PEST Domain Mutants in Cancer	1
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	1
Adipogenesis	1
Respiratory Syncytial Virus Infection Pathway	1
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	1
Signal Transduction	1
Signaling by TGFB family members	1
Signaling by NOTCH	1
Gene expression (Transcription)	1
Signaling by TGF-beta Receptor Complex	1
Generic Transcription Pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
cell cycle process	1
Notch signaling pathway	1
regulation of Notch signaling pathway	1
negative regulation of signal transduction	1
regulation of transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
regulation of DNA-templated transcription	1
cyclin-dependent protein serine/threonine kinase activity	1
cyclin-dependent protein kinase regulator activity	1
protein binding	1
binding	1
serine/threonine protein kinase complex	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
core mediator complex	1
nuclear protein-containing complex	1
nuclear cyclin-dependent protein kinase holoenzyme complex	1

Protein interactions and networks

STRING

2600 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCNC	MED12	Q93074	999
CCNC	CDK8	P49336	999
CCNC	MED13	Q9UHV7	998
CCNC	CDK19	Q9BWU1	997
CCNC	CDK3	Q00526	995
CCNC	MED12L	Q86YW9	993
CCNC	MED13L	Q71F56	987
CCNC	MED6	O75586	929
CCNC	CDK7	P50613	924
CCNC	MED14	O60244	919
CCNC	MED17	Q9NVC6	917
CCNC	MED21	Q13503	893
CCNC	CDK2	P24941	858
CCNC	MED26	O95402	808
CCNC	MED1	Q15648	771

IntAct

409 interactions, top by confidence:

A	B	Type	Score
CCNC	CDK8	psi-mi:“MI:0915”(physical association)	0.980
CDK8	CCNC	psi-mi:“MI:0915”(physical association)	0.980
CDK8	CCNC	psi-mi:“MI:0407”(direct interaction)	0.980
CCNC	CDK8	psi-mi:“MI:0407”(direct interaction)	0.980
CCNC	CDK8	psi-mi:“MI:0914”(association)	0.980
CCNC	CDK8	psi-mi:“MI:2364”(proximity)	0.980
MED10	MED24	psi-mi:“MI:0914”(association)	0.870
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
CDK8	MED19	psi-mi:“MI:0914”(association)	0.850
CCNC	CDK3	psi-mi:“MI:0915”(physical association)	0.750
CCNC	KRT31	psi-mi:“MI:0915”(physical association)	0.720
KRT31	CCNC	psi-mi:“MI:0915”(physical association)	0.720
CRX	CCNC	psi-mi:“MI:0915”(physical association)	0.670
CCNC	ZNF18	psi-mi:“MI:0915”(physical association)	0.670
PBXIP1	CCNC	psi-mi:“MI:0915”(physical association)	0.670
CCNC	PNMA5	psi-mi:“MI:0915”(physical association)	0.670
NMNAT1	CCNC	psi-mi:“MI:0915”(physical association)	0.670
TRIM39	CCNC	psi-mi:“MI:0915”(physical association)	0.670

BioGRID (365): CDK8 (Two-hybrid), CRX (Two-hybrid), GOLGA2 (Two-hybrid), KRT13 (Two-hybrid), KRT15 (Two-hybrid), KRT31 (Two-hybrid), MEOX2 (Two-hybrid), MGST3 (Two-hybrid), NEFL (Two-hybrid), ZNF18 (Two-hybrid), TADA3 (Two-hybrid), PUF60 (Two-hybrid), MBIP (Two-hybrid), TRIM39 (Two-hybrid), PBXIP1 (Two-hybrid)

ESM2 similar proteins: A2VEA3, A5PKA5, B1H1E4, B5FXJ6, O15294, O89050, P24863, P39947, P55168, P56558, P61201, P61202, P61203, P79101, P81436, Q05048, Q13888, Q27HV0, Q28F72, Q32NS4, Q3UHD6, Q3ZCK5, Q4KLA0, Q4R9A8, Q4VC33, Q5BJQ6, Q5F398, Q5R532, Q5R8K2, Q5RB35, Q5RKJ1, Q62447, Q6GR10, Q6IQT4, Q6IR75, Q6PFJ9, Q7L5Y9, Q7SXR3, Q8C6G8, Q8CGY8

Diamond homologs: A1C7R6, A3LPX1, A4RD79, F1QMB9, O75909, O88874, O94503, P24863, P25008, P39947, P47821, P55168, P93411, Q0CV29, Q16JA2, Q1EAW8, Q28F72, Q29AI1, Q2GVK1, Q2UDB2, Q3ZCK5, Q4KLA0, Q4WZT9, Q56YF8, Q5A4H9, Q5BBA8, Q62447, Q6BYF8, Q6CAC7, Q6CP20, Q6FJE8, Q75AX7, Q7QB13, Q86KE7, Q9C1M4, Q9FJK6, Q9FJK7, Q9HE63, P51946, Q3ZBL9

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
CCNC	“up-regulates quantity by expression”	HES1	“transcriptional regulation”
CCNC	down-regulates	NOTCH1	phosphorylation
MAML1	up-regulates	CCNC	relocalization
CCNC	down-regulates	NOTCH	phosphorylation
CCNC	“form complex”	“CKM complex”	binding
CCNC	“form complex”	CyclinC/CDK19	binding
CCNC	“form complex”	CyclinC/CDK3	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 85 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	6	22.3×	3e-05
Epigenetic regulation by WDR5-containing histone modifying complexes	8	21.3×	1e-06
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	6	20.4×	4e-05
Respiratory Syncytial Virus Infection Pathway	5	17.0×	4e-04
Adipogenesis	6	16.2×	1e-04
RSV-host interactions	5	13.5×	1e-03
Epigenetic regulation of gene expression	10	12.3×	1e-06
Regulation of lipid metabolism by PPARalpha	5	12.2×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
morphogenesis of an epithelium	6	26.1×	3e-05
positive regulation of transcription elongation by RNA polymerase II	6	22.9×	4e-05
intermediate filament organization	7	21.3×	2e-05
RNA polymerase II preinitiation complex assembly	5	17.2×	1e-03
epithelial cell differentiation	5	11.1×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

41 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	22
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
4682664	GRCh37/hg19 6q16.1-16.2(chr6:96096962-100369465)x1	Pathogenic
814851	GRCh37/hg19 6q16.1-16.2(chr6:98870687-100270433)x1	Likely pathogenic

SpliceAI

2111 predictions. Top by Δscore:

Variant	Effect	Δscore
6:99545144:A:AC	donor_gain	1.0000
6:99545145:C:CC	donor_gain	1.0000
6:99545230:TCTAG:T	acceptor_loss	1.0000
6:99545231:C:CA	acceptor_loss	1.0000
6:99545231:C:CC	acceptor_gain	1.0000
6:99551896:C:CC	acceptor_gain	1.0000
6:99558495:A:AC	donor_gain	1.0000
6:99558496:C:CC	donor_gain	1.0000
6:99558496:CATA:C	donor_gain	1.0000
6:99561591:TCCTA:T	donor_loss	1.0000
6:99561592:CCTA:C	donor_loss	1.0000
6:99561593:CTAC:C	donor_loss	1.0000
6:99561594:TACC:T	donor_loss	1.0000
6:99561595:A:T	donor_loss	1.0000
6:99561596:CCT:C	donor_loss	1.0000
6:99561677:GATAA:G	acceptor_gain	1.0000
6:99561678:ATAA:A	acceptor_gain	1.0000
6:99561679:TAA:T	acceptor_gain	1.0000
6:99561680:AA:A	acceptor_gain	1.0000
6:99561681:ACTAA:A	acceptor_loss	1.0000
6:99561682:C:CC	acceptor_gain	1.0000
6:99561682:C:CG	acceptor_loss	1.0000
6:99561683:T:G	acceptor_loss	1.0000
6:99562836:GTTTA:G	donor_loss	1.0000
6:99562837:TTTA:T	donor_loss	1.0000
6:99562838:TTA:T	donor_loss	1.0000
6:99562841:C:CG	donor_loss	1.0000
6:99562863:A:C	donor_gain	1.0000
6:99562866:T:TA	donor_gain	1.0000
6:99562867:C:A	donor_gain	1.0000

AlphaMissense

1878 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:99546470:G:C	C201W	1.000
6:99551006:A:G	L142P	1.000
6:99551011:G:C	F140L	1.000
6:99551011:G:T	F140L	1.000
6:99551013:A:G	F140L	1.000
6:99551015:T:A	E139V	1.000
6:99561373:T:A	K96N	1.000
6:99561373:T:G	K96N	1.000
6:99561374:T:A	K96I	1.000
6:99561375:T:C	K96E	1.000
6:99561380:G:T	A94E	1.000
6:99561391:A:C	C90W	1.000
6:99561392:C:T	C90Y	1.000
6:99561393:A:G	C90R	1.000
6:99561608:T:A	R71S	1.000
6:99561608:T:G	R71S	1.000
6:99561627:G:T	A65D	1.000
6:99561628:C:G	A65P	1.000
6:99561633:G:T	A63D	1.000
6:99561666:C:T	G52D	1.000
6:99561667:C:G	G52R	1.000
6:99562941:A:G	W14R	1.000
6:99562941:A:T	W14R	1.000
6:99546427:A:G	W216R	0.999
6:99546427:A:T	W216R	0.999
6:99546459:G:T	A205D	0.999
6:99546468:A:G	L202P	0.999
6:99546471:C:T	C201Y	0.999
6:99546472:A:G	C201R	0.999
6:99549513:G:T	A198D	0.999

dbSNP variants (sampled 300 via entrez): RS1000272882 (6:99546210 C>A,T), RS1000428503 (6:99555028 G>A), RS1000523735 (6:99559660 A>T), RS1000537592 (6:99568079 C>A), RS1000566570 (6:99549992 A>G), RS1000652243 (6:99567881 C>A), RS1000876217 (6:99564496 A>G), RS1000957856 (6:99559212 T>C), RS1001040696 (6:99552041 T>C), RS1001078298 (6:99542397 G>GA), RS1001354052 (6:99547144 T>C), RS1001593083 (6:99551487 T>G), RS1001881104 (6:99565915 C>T), RS1001922786 (6:99551122 T>C), RS1002031061 (6:99558378 G>A,T)

Disease associations

OMIM: gene MIM:123838 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (2): autism (MONDO:0005260), CIC-rearranged sarcoma (MONDO:0956989)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST007118_1	Erectile dysfunction	2.000000e-37
GCST010002_330	Refractive error	2.000000e-15
GCST011494_33	Daytime nap	3.000000e-10
GCST012419_6	Longevity (100 years and older)	4.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007828	daytime rest measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (5): CHEMBL2401607 (SINGLE PROTEIN), CHEMBL3038474 (PROTEIN COMPLEX), CHEMBL3883323 (PROTEIN COMPLEX), CHEMBL4888443 (PROTEIN COMPLEX), CHEMBL4888454 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 86,276 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1336	SORAFENIB	4	86,060
CHEMBL5199065	ISTISOCICLIB	2	21
CHEMBL4076837	SENEXIN B	1	104
CHEMBL4225966	SEL-120 FREE BASE	1	91

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

93 measured of 97 human assays (97 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
5-cyclopropyl-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	0.48 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-ethylspiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,1’-cyclohexane]-4-carboxamide	IC50	0.77 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-(2-fluoroethyl)spiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,1’-cyclobutane]-4-carboxamide	IC50	0.827 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-ethyl-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	1.09 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
spiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,1’-cyclobutane]-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3,7,7-trimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
13-chloro-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(13),2(6),4,9,11-pentaene-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-(2-fluoroethyl)-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
7-cyclohexyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-ethylspiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,1’-cyclobutane]-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-methylspiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,1’-cyclobutane]-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-methylspiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,1’-cyclohexane]-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
(7S)-7-cyclohexyl-3-ethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
(7R)-7-cyclohexyl-3-ethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	1.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
5-chloro-3-ethylspiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,4’-oxane]-4-carboxamide	IC50	2.41 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
5-cyclopropyl-3-ethyl-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	2.65 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
spiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,1’-cyclohexane]-4-carboxylic acid	IC50	3.01 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-ethyl-1’-(2,2,2-trifluoroethyl)spiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,4’-piperidine]-4-carboxamide	IC50	3.14 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
(7S)-7-(oxan-4-yl)-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	4.46 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-ethylspiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,4’-oxane]-4-carboxamide	IC50	4.58 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-methylspiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,4’-oxane]-4-carboxamide	IC50	6.1 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
1’-acetylspiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,4’-piperidine]-4-carboxamide	IC50	7.48 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
spiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,1’-cyclohexane]-4-carboxamide	IC50	8.22 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
(7S)-7-cyclohexyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	8.5 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-(2-methoxyethyl)-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	11.5 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	11.9 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-ethyl-5-(3-methoxyphenyl)-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	13.9 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
7-methyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	14.4 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-ethyl-5-(2-methoxyphenyl)-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	16.4 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
5-chloro-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	16.6 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-ethyl-7,7-dimethyl-5-[2-(trifluoromethyl)phenyl]-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	16.7 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
(7R)-7-cyclohexyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	19.3 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
7,7-dimethyl-3-(2,2,2-trifluoroethyl)-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	19.4 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
7,7-dimethyl-5-(4-sulfamoylphenyl)-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxylic acid	IC50	20.7 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-(2-methoxyethyl)spiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,4’-oxane]-4-carboxamide	IC50	20.9 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
5-ethenyl-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	29.5 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
7-methyl-7-propan-2-yl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	31.1 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
13-chloro-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(13),2(6),4,9,11-pentaene-4-carboxylic acid	IC50	31.4 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
1’-(2,2,2-trifluoroethyl)spiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,4’-piperidine]-4-carboxamide	IC50	40.5 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
5-(3,6-dihydro-2H-pyran-4-yl)-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	70.5 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
7,7-dimethyl-5-(4-sulfamoylphenyl)-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	81.3 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
5-(3,6-dihydro-2H-pyran-4-yl)-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxylic acid	IC50	86.6 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-(2-fluoroethyl)-5-(2-methoxyphenyl)-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	97.3 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
7,7-dimethyl-5-phenyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	107 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
5-(2-hydroxyphenyl)-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	112 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
1’-(3,3,3-trifluoropropyl)spiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,4’-piperidine]-4-carboxamide	IC50	120 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
5-(3-methoxyphenyl)-7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxamide	IC50	127 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
7,7-dimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-4-carboxylic acid	IC50	146 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
3-(2-fluoroethyl)spiro[8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2(6),4,10,12-pentaene-7,1’-cyclohexane]-4-carboxamide	IC50	148 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors
13-chloro-3,7,7-trimethyl-8-oxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(13),2(6),4,9,11-pentaene-4-carboxamide	IC50	158 nM	US-10208056: Condensed tricyclic compounds as protein kinase inhibitors

ChEMBL bioactivities

846 potent at pChembl≥5 of 848 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.72	IC50	0.191	nM	CHEMBL4789125
9.70	IC50	0.2	nM	CHEMBL4078454
9.58	IC50	0.262	nM	CHEMBL4789603
9.56	IC50	0.278	nM	CHEMBL4776812
9.50	IC50	0.314	nM	CHEMBL4777356
9.47	IC50	0.34	nM	CHEMBL4083552
9.44	IC50	0.36	nM	CHEMBL4061525
9.43	IC50	0.37	nM	CHEMBL5435821
9.40	IC50	0.4	nM	CHEMBL4096487
9.40	IC50	0.4	nM	CHEMBL5434183
9.40	IC50	0.4	nM	CHEMBL5409410
9.39	IC50	0.407	nM	CHEMBL5752178
9.34	IC50	0.46	nM	CHEMBL4066819
9.33	IC50	0.47	nM	CHEMBL4070408
9.33	IC50	0.466	nM	CHEMBL4780792
9.32	IC50	0.48	nM	CHEMBL5405004
9.32	IC50	0.48	nM	CHEMBL4792305
9.31	IC50	0.49	nM	CHEMBL5414359
9.27	IC50	0.54	nM	CHEMBL4091527
9.26	IC50	0.55	nM	CHEMBL4083552
9.24	IC50	0.57	nM	CHEMBL4086487
9.23	IC50	0.59	nM	CHEMBL4061525
9.22	IC50	0.6	nM	CHEMBL4074204
9.20	IC50	0.63	nM	CHEMBL5416117
9.19	IC50	0.65	nM	CHEMBL4082469
9.15	IC50	0.7	nM	CHEMBL498385
9.15	IC50	0.71	nM	CHEMBL3828221
9.15	IC50	0.71	nM	CHEMBL5402477
9.15	IC50	0.7	nM	CHEMBL5396725
9.11	IC50	0.77	nM	CHEMBL4070408
9.11	IC50	0.77	nM	CHEMBL4777356
9.10	Kd	0.7943	nM	CHEMBL6163999
9.08	IC50	0.83	nM	CHEMBL5411825
9.08	IC50	0.827	nM	CHEMBL4789603
9.06	IC50	0.88	nM	CHEMBL5440319
9.05	IC50	0.9	nM	CHEMBL3828637
9.05	IC50	0.9	nM	CHEMBL5416758
9.03	IC50	0.93	nM	CHEMBL4060856
9.01	IC50	0.97	nM	CHEMBL4060856
9.00	IC50	1	nM	CHEMBL3799396
9.00	IC50	1	nM	CHEMBL3806220
9.00	IC50	1	nM	CHEMBL3828458
9.00	IC50	1	nM	CHEMBL4076395
9.00	IC50	0.99	nM	CHEMBL4066819
9.00	IC50	0.99	nM	CHEMBL4062244
9.00	IC50	1	nM	CHEMBL4455382
9.00	IC50	1	nM	CHEMBL4877883
9.00	IC50	1	nM	CHEMBL4856177
9.00	IC50	1	nM	CHEMBL6044863
8.96	IC50	1.1	nM	CHEMBL3805960

PubChem BioAssay actives

640 with measured affinity, of 1156 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-chloro-4-[6-[[(1R)-2-hydroxy-1-phenylethyl]amino]pyrazin-2-yl]phenol	1474371: Inhibition of full length recombinant human His-tagged CDK8/Cyclin C expressed in baculovirus expression system using Ulight-GS peptide as substrate measured after 30 mins by TR-FRET based LANCE assay	ic50	0.0002	uM
8-phenoxy-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0003	uM
8-[[6-(methylamino)-3-pyridinyl]oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474369: Inhibition of kinase tracer-236 binding to GST-tagged CDK19/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0004	uM
5-[(5S)-5-(4-chlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]-3-methyl-2H-indazole	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0004	uM
5-[5-[(4-chlorophenyl)methyl]-1-methyltriazol-4-yl]-3-methyl-2H-indazole	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0004	uM
(5S)-5-(4-chlorophenyl)-3-(3-methyl-2H-indazol-5-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0004	uM
(2R)-2-[[5-(1H-indazol-5-yl)-3-pyridinyl]amino]-2-phenylethanol	1474371: Inhibition of full length recombinant human His-tagged CDK8/Cyclin C expressed in baculovirus expression system using Ulight-GS peptide as substrate measured after 30 mins by TR-FRET based LANCE assay	ic50	0.0004	uM
8-[[6-(2-methoxyethylcarbamoyl)-3-pyridinyl]oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0005	uM
8-[(2-methyl-3-pyridinyl)oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0005	uM
(E)-N-[4-(morpholin-4-ylmethyl)phenyl]-3-[4-(1H-pyrazol-4-yl)-3-pyridinyl]prop-2-enamide	1466029: Inhibition of kinase tracer 236 binding to full length N terminal GST-tagged human CDK8 (1 to 464 end residues) /CycC ( 1 to 283 end residues) expressed in baculovirus expression system after 60 min by TR-FRET assay	ic50	0.0005	uM
5-[4-[(4-chlorophenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-3-methyl-2H-indazole	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0005	uM
(5R)-5-(4-chlorophenyl)-3-(3-methyl-2H-indazol-5-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0005	uM
8-methylsulfanyl-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0006	uM
8-[(6-amino-3-pyridinyl)oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0006	uM
8-[(6-acetamido-3-pyridinyl)oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0006	uM
(5R)-5-(4-chlorophenyl)-3-(3-methyl-2H-indazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[3,4-c][1,4]oxazine	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0006	uM
2-(1-methylimidazol-2-yl)-8-[4-(1-methylpyrazol-4-yl)phenyl]-1,6-naphthyridine	1313396: Competitive binding affinity to full length His-tagged human recombinant CDK8/cyclin C expressed in baculovirus after 20 mins in presence of Alexa647 tracer by FRET assay	ic50	0.0007	uM
3-methyl-5-[5-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-triazol-3-yl]-2H-indazole	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0007	uM
5-[5-[(4-chlorophenyl)methyl]-1-methylpyrazol-4-yl]-3-methyl-2H-indazole	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0007	uM
4-(4-iodophenoxy)-2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridine	1299821: Inhibition of full length human recombinant His-tagged CDK8/Cyclin C expressed in baculovirus expression system by fluorescence polarization assay	ic50	0.0007	uM
(5R)-5-(4-chlorophenyl)-7-methyl-3-(3-methyl-2H-indazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0008	uM
N-methyl-8-(1-methyl-2,2-dioxo-3H-2,1-benzothiazol-5-yl)-1,6-naphthyridine-2-carboxamide	1313396: Competitive binding affinity to full length His-tagged human recombinant CDK8/cyclin C expressed in baculovirus after 20 mins in presence of Alexa647 tracer by FRET assay	ic50	0.0009	uM
8-[(6-carbamoyl-3-pyridinyl)oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0009	uM
5-[(5S)-5-(4-chlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]-3-methyl-2H-pyrazolo[4,3-b]pyridine	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0009	uM
3-chloro-5-[4-[(4-chlorophenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-2H-indazole	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0009	uM
8-[3-chloro-5-(1-methyl-2,2-dioxo-3H-2,1-benzothiazol-5-yl)-4-pyridinyl]-1-methyl-2,3,8-triazaspiro[4.5]dec-1-en-4-one	1295765: Binding affinity to human CDK19 (1 to 502 amino acid residues)/Cyclin C (1 to 283 amino acid residues) by reporter displacement assay	ic50	0.0010	uM
1-[8-[4-(1-methylpyrazol-4-yl)phenyl]-1,6-naphthyridin-2-yl]imidazolidin-2-one	1313396: Competitive binding affinity to full length His-tagged human recombinant CDK8/cyclin C expressed in baculovirus after 20 mins in presence of Alexa647 tracer by FRET assay	ic50	0.0010	uM
8-[[6-(methylcarbamoyl)-3-pyridinyl]oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474369: Inhibition of kinase tracer-236 binding to GST-tagged CDK19/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0010	uM
8-[(6-methyl-3-pyridinyl)oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0010	uM
4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxybenzonitrile	1299821: Inhibition of full length human recombinant His-tagged CDK8/Cyclin C expressed in baculovirus expression system by fluorescence polarization assay	ic50	0.0010	uM
2-[4-(4-isoquinolin-4-ylphenyl)pyrazol-1-yl]-N,N-dimethylacetamide	1541941: Inhibition of CDK8/CyclinC (unknown origin)	ic50	0.0010	uM
8-[3-chloro-5-(1-methylindazol-5-yl)-2H-pyrazolo[3,4-b]pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one	1769449: Inhibition of tracer 236 binding to recombinant human His-tagged full length CDK8/Cyclin C expressed in baculovirus expression system by Lanthascreen assay	ic50	0.0010	uM
4-(4-methylpiperazin-1-yl)-N-[4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-yl]quinolin-7-amine	1771106: Inhibition of human CDK8/cyclin C incubated for 2 hrs by [gamma-33P]-ATP assay	ic50	0.0010	uM
[5-amino-8-[4-(1-methylpyrazol-4-yl)phenyl]-1,6-naphthyridin-2-yl]-(3-methoxyazetidin-1-yl)methanone	1313396: Competitive binding affinity to full length His-tagged human recombinant CDK8/cyclin C expressed in baculovirus after 20 mins in presence of Alexa647 tracer by FRET assay	ic50	0.0011	uM
8-[[6-(2-ethoxyethylcarbamoyl)-3-pyridinyl]oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0011	uM
2-(2H-tetrazol-5-yl)-4-[4-(trifluoromethoxy)phenoxy]thieno[2,3-c]pyridine	1299821: Inhibition of full length human recombinant His-tagged CDK8/Cyclin C expressed in baculovirus expression system by fluorescence polarization assay	ic50	0.0011	uM
4-(4-chlorophenoxy)-2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridine	1299821: Inhibition of full length human recombinant His-tagged CDK8/Cyclin C expressed in baculovirus expression system by fluorescence polarization assay	ic50	0.0011	uM
N-(4-propan-2-ylphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine	1921466: Inhibition of CDK8/Cyclin C (unknown origin) by LanthaScreen binding assay	ic50	0.0011	uM
[(2S)-2-(4-chlorophenyl)pyrrolidin-1-yl]-(3-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)methanone	1315916: Inhibition of Alexa647 tracer binding to full length recombinant human His-tagged CDK8/cyclin C expressed in Baculovirus expression system preincubated for 20 mins followed by tracer addition and incubated in dark for 60 mins by FRET-based Lanthascreen assay	ic50	0.0013	uM
8-[[6-(2-methoxyethylcarbamoyl)-2-methyl-3-pyridinyl]oxy]-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474369: Inhibition of kinase tracer-236 binding to GST-tagged CDK19/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0013	uM
8-[3-chloro-5-[4-[1-(2-hydroxy-2-methylpropyl)pyrazol-4-yl]phenyl]-4-pyridinyl]-2,8-diazaspiro[4.5]decan-1-one	1295765: Binding affinity to human CDK19 (1 to 502 amino acid residues)/Cyclin C (1 to 283 amino acid residues) by reporter displacement assay	ic50	0.0014	uM
4-[2-[6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl]ethylamino]quinoline-6-carbonitrile	1825673: Binding affinity to kinase tracer 236 binding to His tagged recombinant human CDK8/cyclinC assessed as dissociation constant by TR FRET based assay	kd	0.0014	uM
[(2S)-2-(4-chlorophenyl)pyrrolidin-1-yl]-(3-methyl-2H-indazol-5-yl)methanone	1315916: Inhibition of Alexa647 tracer binding to full length recombinant human His-tagged CDK8/cyclin C expressed in Baculovirus expression system preincubated for 20 mins followed by tracer addition and incubated in dark for 60 mins by FRET-based Lanthascreen assay	ic50	0.0014	uM
8-[4-(1-methylpyrazol-4-yl)phenyl]-1,6-naphthyridine-2-carboxamide	1313396: Competitive binding affinity to full length His-tagged human recombinant CDK8/cyclin C expressed in baculovirus after 20 mins in presence of Alexa647 tracer by FRET assay	ic50	0.0015	uM
8-pyridin-3-yloxy-4,5-dihydrothieno[3,4-g][1,2]benzothiazole-6-carboxamide	1474368: Inhibition of kinase tracer-236 binding to GST-tagged CDK8/CyclinC (unknown origin) after 60 mins by TR-FRET assay	ic50	0.0015	uM
(E)-3-[4-(3H-benzimidazol-5-yl)-3-pyridinyl]-N-[4-(morpholin-4-ylmethyl)phenyl]prop-2-enamide	1466029: Inhibition of kinase tracer 236 binding to full length N terminal GST-tagged human CDK8 (1 to 464 end residues) /CycC ( 1 to 283 end residues) expressed in baculovirus expression system after 60 min by TR-FRET assay	ic50	0.0015	uM
7-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide	1299821: Inhibition of full length human recombinant His-tagged CDK8/Cyclin C expressed in baculovirus expression system by fluorescence polarization assay	ic50	0.0015	uM
5-[(5S)-5-(4-chlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]-3-methyl-2H-pyrazolo[3,4-b]pyridine	2030640: Inhibition of His tagged human recombinant CDK8/Cyclin C expressed in baculovirus expression system incubated for 15 mins by FRET-based LanthaScreen binding competition assay	ic50	0.0015	uM
4-(4-methylphenoxy)-2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridine	1299821: Inhibition of full length human recombinant His-tagged CDK8/Cyclin C expressed in baculovirus expression system by fluorescence polarization assay	ic50	0.0016	uM
1-methyl-8-[(2-methyl-3-pyridinyl)oxy]-4,5-dihydrothieno[3,4-g]indazole-6-carboxamide	1613762: Displacement of Kinase tracer 236 from recombinant full-length human N-terminal GST-fused CDK8 (1 to 464 residues)/cyclin C (1 to 283 residues) expressed in baculovirus expression system after 60 mins by TR-FRET assay	ic50	0.0016	uM

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression, affects cotreatment, increases abundance	3
usnic acid	affects cotreatment, decreases expression, increases expression	2
perfluorooctane sulfonic acid	decreases expression	2
Arsenic	increases expression, affects cotreatment, increases abundance	2
Calcitriol	decreases expression, increases expression	2
Nanotubes, Carbon	decreases expression, increases expression	2
bisphenol F	affects cotreatment, decreases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
beta-methylcholine	affects expression	1
inecalcitol	decreases expression	1
jinfukang	decreases expression	1
bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV)	increases expression	1
Rosiglitazone	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Dihydroxyacetone	increases expression	1
Environmental Pollutants	affects expression	1
Flame Retardants	increases expression	1
Fluorouracil	decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Metformin	affects cotreatment, decreases expression	1
Paraquat	increases expression	1
Parathion	increases expression	1
Piroxicam	decreases expression	1

ChEMBL screening assays

226 unique, capped per target: 226 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5383245	Binding	PROTAC activity at Cyclin C in human MDA-MB-468 cells assessed as degradation of Cyclin C incubated for 48 hrs by Western blotting analysis	Discovery of LL-K8-22: A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex. — J Med Chem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms